PH-15 is under clinical development by VistaGen Therapeutics and currently in Phase I for Cognitive Impairment. According to GlobalData, Phase I drugs for Cognitive Impairment does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PH-15 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PH-15 overview
PH-15 is under development for cognitive enhancement. The therapeutic candidate is administered intranasally as spray. PH-15 belongs to a family of pharmaceutical compounds called pherines. It acts by targeting GPC-peripheral receptors.
VistaGen Therapeutics overview
VistaGen Therapeutics (VistaGen) is a clinical stage biopharmaceutical company that develops new generation medicines for depression and neuropsychiatric disorders. The company’s pipeline product, AV-101, currently under Phase 2 clinical development, is an oral N-methyl-D-aspartate receptor glycine B intended to treat the major depressive disorder. Its other pipeline products comprise of PH94B treats social anxiety disorder and PH10 nasal spray treats for major depressive disorder. The company offers its products in the form of sprays and oral. It partners with other healthcare industries for researching and assessing drug effects on cardiac risk. VistaGen is headquartered in South San Francisco, California, the US.
For a complete picture of PH-15’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.